Buy HITI by Jun 16, 2027.

**Officinal PR :** [https://www.newswire.ca/news-releases/high-tide-reports-second-quarter-2026-financial-results-featuring-record-revenue-of-179-3mm-and-adjusted-ebitda-of-13-9mm-889092761.html](https://www.newswire.ca/news-releases/high-tide-reports-second-quarter-2026-financial-results-featuring-record-revenue-of-179-3mm-and-adjusted-ebitda-of-13-9mm-889092761.html) **Q2 FY2026: $179.3M revenue (+30% YoY, fastest growth in 11 quarters), record $13.9M Adjusted EBITDA (+73% YoY), positive net income and free cash flow, plus a $40M BMO credit agreement.** HITI is becoming the definition of non-stop execution and deserves more credit for this. Remexian's goal is clear: gain more market share to satisfy this insatiable and ever-growing demand, in order to reach 20-30% market share in the long term and then achieve pricing determination with …